icon-avatar
Economía

COMUNICADO: Nuevos datos muestran la buena eficacia y perfil de seguridad de flutiform® en pacientes asmáticos (y 2)

    [4] Global Initiative for Asthma (GINA). Global burden of asthma report. 2004. Disponible en: http://www.ginasthma.com/ReportItem.asp?l1=2&l2=2&intId=94. Acceso el 22 de agosto de 2011

    [5] Masoli M, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004 May;59(5):469-78

    [6] Braman SS. The global burden of asthma. Chest 2006;130(1 Suppl):4S-12S

    [7] Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2010. Available at: http://www.ginasthma.org/guidelines-gina-report-global-strategy-for-asthma.html . Acceso el 22 de agosto de 2011

    [8] Bodzenta-Lukaszyk A, et al, Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler: Respiratory Medicine. 2011; 105:5, 674-682

    [9] Bodzenta-Lukaszyk A, et al.Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma. BMC Pulm Med. 2011. doi:1471-2466/11/28

    CONTACTO: Para más información, contacte con: Millan Saez, Jose Ramon.joseramon.millan@mundipharma.es , +34-91-382-26-85; Traseira, Susana, susana.traseira@mundipharma.es , +34-91-382-18-70

    Relacionados

    WhatsAppFacebookFacebookTwitterTwitterLinkedinLinkedinBeloudBeloudBluesky